RxDoctor Payments Data

Zachary Cohen, MD

Pain Medicine · San Diego, CANPI 1598021982

Payments from drug & device makers

$36,167in general payments, 2019–2025

Across 914 payments — averaging $39.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$9K
  • Boston Scientific$6K
  • Medtronic$5K
  • Abbott$4K
  • Relievant Medsystems, Inc.$2K
  • Curonix LLC$1K
  • plus $9K from 52 others

What the payments were for

  • Speaking & faculty fees$2,5507%
  • Travel & lodging$3,54310%
  • Food & beverage$29,77582%
  • Education$210%
  • Entertainment$2781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nevro Corp.180$8,514
Boston Scientific145$6,463
Medtronic(2 entities)107$5,283
Abbott88$3,636
Relievant Medsystems, Inc.16$1,541
Curonix LLC34$1,286
Si-bone, Inc.18$1,016
Vertiflex, Inc.8$971
Forte Bio-pharma LLC51$869
Vertos Medical, Inc.8$834
Nalu Medical, Inc.43$822
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$538
Collegium Pharmaceutical, Inc.23$397
Foundation Fusion Solutions, LLC2$375
Axonics, Inc.4$310
Scilex Pharmaceuticals Inc.19$290
Bioness Inc1$278
Amgen11$259
AbbVie(2 entities)18$256
Flowonix Medical Incorporated1$200
Biodelivery Sciences International, Inc.15$186
Painteq LLC6$178
Spinal Simplicity, LLC3$162
Zyla Life Sciences, Inc.15$144
Biohaven Pharmaceuticals, Inc.8$123
Saluda Medical Americas, Inc.4$89
Merz North America, Inc.1$74
SPR Therapeutics, Inc1$73
Avanir Pharmaceuticals, Inc.4$72
Impel Pharmaceuticals Inc.3$70
Johnson & Johnson3$69
Novartis3$57
Teva Pharmaceuticals USA, Inc.3$57
Merz Pharmaceuticals, LLC2$53
Pfizer2$46
Lundbeck LLC2$42
Alnylam Pharmaceuticals Inc.2$39
Biotronik NRO, Inc.1$36
Lilly USA, LLC2$35
Kowa Pharmaceuticals America, Inc.2$35
Hikma Pharmaceuticals USA2$33
Almatica Pharma LLC2$32
Arbor Pharmaceuticals, Inc.2$30
Vanda Pharmaceuticals Inc.1$26
Biohaven Pharmaceutical Holding Company Ltd.1$25
Biogen1$25
Novo Nordisk1$25
AstraZeneca1$24
Stimwave Technologies Incorporated2$24
Fidia Pharma USA Inc.1$24
Pacira Therapeutics, Inc.1$19
CSL Behring1$19
Tanabe Pharma America, Inc.1$16
Sanofi1$15
Azurity Pharmaceuticals, Inc.1$15
Redhill Biopharma Inc.1$14
Medline Industries LP1$13
Vision Quest Industries Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,167 in reported general payments places this provider in the 90th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$271,224
Medicare patients
542
Services billed
2,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl31$27,758
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen120$19,215
Buprenorphine28$6,281
OxycontinOxycodone Hcl16$6,224
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen189$5,119
Naloxone Hcl78$4,663
Methocarbamol47$3,062
Lidocaine32$2,776
Celecoxib74$2,684
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$2,633
Gabapentin111$1,468
Oxycodone Hcl64$918
Cyclobenzaprine Hcl71$843
Tizanidine Hcl57$809
Pregabalin46$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$397$27,75831 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl$33$9,20054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 pain medicine providers in California.

Other pain medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →